Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs have gained immense popularity in Peru due to the high incidence of respiratory diseases in the country. The market for bronchodilator drugs has been on the rise in Peru, with a growing number of people suffering from respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis.
Customer preferences: Peruvian customers prefer bronchodilator drugs that are effective in treating respiratory diseases and have minimal side effects. They also prefer drugs that are affordable and easily accessible. As a result, there has been a rise in the demand for generic bronchodilator drugs in Peru.
Trends in the market: One of the major trends in the bronchodilator drugs market in Peru is the increasing demand for combination drugs. Combination drugs are more effective in treating respiratory diseases as they contain two or more active ingredients that work together to provide relief. Another trend is the growing popularity of long-acting bronchodilator drugs, which provide relief for a longer duration and reduce the need for frequent dosing.
Local special circumstances: Peru has a high altitude, with many cities located above 2,500 meters. This altitude can cause respiratory problems in people who are not acclimatized to it. As a result, there is a high incidence of respiratory diseases in Peru, making the bronchodilator drugs market a vital part of the country's healthcare system.
Underlying macroeconomic factors: Peru has a growing economy, which has led to an increase in healthcare spending. The government has also implemented policies to increase access to healthcare for the population, which has further boosted the demand for bronchodilator drugs. Additionally, the rise in air pollution levels in Peru's major cities has led to an increase in respiratory illnesses, further driving the growth of the bronchodilator drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
